Galmed Pharmaceuticals declined 2% to close at $3.42 on March 18 after the clinical-stage biopharmaceutical company posted a wider-than-feared loss in the fourth …
It’s a big day for Galmed Pharmaceuticals (NASDAQ:GLMD). The drug maker released positive phase Phase 2b data for Aramchol in NASH that had many, even …
Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Galmed Pharmaceuticals …
In a research note issued today, Maxim Group analyst Jason Kolbert assigned a Buy rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) with a $24 price target, …